SCHEDULE 13G/A: BlackRock Discloses 14.2% Passive Stake in Dynavax Technologies
Beneficial Ownership Statement
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 14.2% beneficial ownership stake in Dynavax Technologies Corp., primarily for passive investment purposes.
Summary
- BlackRock, Inc. reported beneficial ownership of 17,009,915 shares of Dynavax Technologies Corp. common stock as of June 30, 2025.
- This ownership represents 14.2% of the total outstanding common stock of Dynavax Technologies Corp.
- BlackRock holds sole voting power over 16,813,227 shares and sole dispositive power over 17,009,915 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- iShares Core S&P Small-Cap ETF and BlackRock Fund Advisors are identified as entities within BlackRock's structure that each beneficially own 5% or greater of the outstanding shares of Dynavax Technologies Corp.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing beneficial ownership, which is neutral in sentiment. It does not contain positive or negative performance indicators or strategic updates from the issuer.
Positives
- The disclosure of a significant 14.2% stake by a major institutional investor like BlackRock, Inc. indicates substantial institutional interest and confidence in Dynavax Technologies Corp.
Future Outlook
No forward-looking statements or guidance are provided in this beneficial ownership filing.
Industry Context
This filing is a routine disclosure by BlackRock, Inc., one of the world's largest asset managers, detailing its passive investment stake in Dynavax Technologies Corp., a biotechnology company. Such disclosures are common for large institutional investors as part of their diversified portfolio management and regulatory compliance.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake in the company.
- Investors: Offers insight into the level of institutional interest in Dynavax Technologies Corp.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which has been expressly revoked by the new Power of Attorney. |
| 2025-01-21 | Effective date of the new Power of Attorney granted by BlackRock, Inc. |
| 2025-06-30 | Date of the event which required the filing of this Schedule 13G statement. |
| 2025-07-17 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
BlackRock, Dynavax Technologies, Schedule 13G, beneficial ownership, institutional investment, common stock, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.